Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology

Long-Term Monitoring and Future Risks in GD1

At a Glance

Successfully managing Gaucher disease type 1 (GD1) requires lifelong monitoring through routine blood work and imaging. Tracking biomarkers like Lyso-Gb1 helps ensure your care plan is working, while proactive screening helps detect secondary risks like Parkinson's disease and MGUS early.

Successfully managing Gaucher disease type 1 (GD1) requires long-term vigilance. Your care team will use a combination of blood tests and advanced imaging to ensure your treatment is working and to watch for secondary health risks [1][2].

Your Surveillance Schedule

A typical monitoring schedule for a stabilized patient includes:

  • Every 6–12 Months:
    • Blood Counts: Tracking platelets and hemoglobin [1].
    • Biomarkers: Measuring Lyso-Gb1 to track your disease burden [3][4].
    • Liver and Kidney Function: Standard labs to ensure medication safety [1].
  • Every 1–2 Years:
    • Bone Marrow MRI: A specialized MRI to calculate a “marrow burden score,” showing how many Gaucher cells are still in your bones [5][6].
    • DXA Scan (Bone Density Scan): This measures bone mineral density to monitor for osteoporosis or an increased risk of fractures [7][8].
    • Organ Volume Assessment: Ultrasound or MRI to monitor the size of your liver and spleen [1].

Understanding Long-Term Health Risks

Decades of research have shown that people with GD1 have an increased risk of two specific conditions compared to the general population. Knowing these risks is meant to empower you with tools for early detection.

1. Parkinson’s Disease (PD)

There is a well-established genetic link between mutations in the GBA1 gene and Parkinson’s disease [9][10].

  • The Risk in Perspective: While the risk is higher than in the general population, the absolute risk remains relatively low. Longitudinal data shows a prevalence of about 4.0% at age 60 and 12.2% at age 80 [11]. The vast majority of people with GD1 will never develop Parkinson’s [12].
  • Proactive Monitoring: Doctors look for “prodromal” (early) signs, such as a reduced sense of smell (hyposmia) or acting out dreams (REM sleep behavior disorder) [13][14].

2. Multiple Myeloma and MGUS

The chronic inflammation caused by Gaucher cells can sometimes lead to a condition called MGUS (Monoclonal Gammopathy of Undetermined Significance) [15][16].

  • The Risk: MGUS involves an abnormal protein in the blood. In a small percentage of cases, it can progress to multiple myeloma, a type of blood cancer [15][17].
  • Proactive Monitoring: Your doctor can add a test called Serum Protein Electrophoresis (SPEP) to your annual bloodwork [15][18]. This test looks for a “monoclonal spike” in your proteins. If found, your doctor will monitor you more closely, as early detection significantly improves outcomes.

The Power of Data

The most important tool in your long-term care is your own history. By tracking your Lyso-Gb1 levels and your MRI marrow scores over several years, you and your doctor can see exactly how the disease is behaving in your body [4][6].

Common questions in this guide

How often do I need a bone marrow MRI for GD1?
A typical monitoring schedule for GD1 includes a specialized bone marrow MRI every 1 to 2 years. This imaging test calculates a marrow burden score, which helps your doctor see how many Gaucher cells remain in your bones.
Why do doctors monitor for Parkinson's disease if I have GD1?
People with Gaucher disease type 1 have mutations in the GBA1 gene, which are genetically linked to a slightly increased risk of Parkinson's disease. While most patients will never develop the condition, doctors monitor for early signs like a reduced sense of smell or changes in sleep patterns.
What is an SPEP test and why is it part of my annual bloodwork?
Serum Protein Electrophoresis (SPEP) is a blood test that detects abnormal proteins. It is used in GD1 patients to monitor for a condition called MGUS, which can develop due to chronic inflammation and may occasionally progress to multiple myeloma.
How does the Lyso-Gb1 blood test help manage my GD1?
The Lyso-Gb1 test measures a specific biomarker to track your disease burden. By checking these levels every 6 to 12 months, you and your doctor can see how active the disease is and determine if your treatment plan is working effectively.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often do I need a whole-body MRI to check my bone marrow burden score?
  2. 2.Can we add a Serum Protein Electrophoresis (SPEP) test to my annual bloodwork to monitor for MGUS?
  3. 3.If I notice a change in my sense of smell or sleep patterns, should I see a neurologist who specializes in GBA-related conditions?
  4. 4.How do we decide if my treatment dose needs adjustment based on my long-term imaging results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

    Biegstraaten M, Cox TM, Belmatoug N, et al.

    Blood cells, molecules & diseases 2018; (68()):203-208 doi:10.1016/j.bcmd.2016.10.008.

    PMID: 28274788
  2. 2

    Population-based cohort of 500 patients with Gaucher disease in Israel.

    Jaffe DH, Flaks-Manov N, Benis A, et al.

    BMJ open 2019; (9(1)):e024251 doi:10.1136/bmjopen-2018-024251.

    PMID: 30670517
  3. 3

    The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease.

    Stiles AR, Huggins E, Fierro L, et al.

    Molecular genetics and metabolism reports 2021; (27()):100729 doi:10.1016/j.ymgmr.2021.100729.

    PMID: 33614410
  4. 4

    Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.

    Peterschmitt MJ, Foster MC, Ji AJ, et al.

    Molecular genetics and metabolism 2023; (138(3)):107527 doi:10.1016/j.ymgme.2023.107527.

    PMID: 36739645
  5. 5

    Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.

    Laudemann K, Moos L, Mengel KE, et al.

    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2015; (187(12)):1093-8 doi:10.1055/s-0035-1553362.

    PMID: 26200566
  6. 6

    Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.

    Laudemann K, Moos L, Mengel E, et al.

    Blood cells, molecules & diseases 2016; (57()):35-41.

    PMID: 26852653
  7. 7

    Radiographic Cortical Thickness Index Predicts Fragility Fracture in Gaucher Disease.

    D'Amore S, Sano H, Chappell DDG, et al.

    Radiology 2023; (307(1)):e212779 doi:10.1148/radiol.212779.

    PMID: 36537898
  8. 8

    Gaucher Disease in Bone: From Pathophysiology to Practice.

    Hughes D, Mikosch P, Belmatoug N, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019; (34(6)):996-1013 doi:10.1002/jbmr.3734.

    PMID: 31233632
  9. 9

    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.

    Avenali M, Cerri S, Ongari G, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(5)):1267-1272 doi:10.1002/mds.28496.

    PMID: 33617695
  10. 10

    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.

    Omer N, Giladi N, Gurevich T, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(1)):190-195 doi:10.1002/mds.28792.

    PMID: 34550621
  11. 11

    Age-Specific Parkinson Disease Risk in Gaucher Disease Type 1: Data From the ICGG Gaucher Registry.

    Alcalay RN, Mistry P, Di Fonzo A, et al.

    Neurology 2026; (106(10)):e214986 doi:10.1212/WNL.0000000000214986.

    PMID: 42085646
  12. 12

    Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.

    Schierding W, Farrow S, Fadason T, et al.

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1346-1356 doi:10.1002/mds.28144.

    PMID: 32557794
  13. 13

    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.

    Nigam M, Ayadi I, Noiray C, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(10)):2431-2435 doi:10.1002/mds.28692.

    PMID: 34117799
  14. 14

    Sleep aspects on video-polysomnography in LRRK2 mutation carriers.

    Ehrminger M, Leu-Semenescu S, Cormier F, et al.

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(13)):1839-43 doi:10.1002/mds.26412.

    PMID: 26468079
  15. 15

    Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.

    Rosenbloom BE, Cappellini MD, Weinreb NJ, et al.

    American journal of hematology 2022; (97(10)):1337-1347 doi:10.1002/ajh.26675.

    PMID: 36054609
  16. 16

    Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States.

    Abell K, Chadwell SE, Burrow TA, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2020; (184(4)):1052-1059 doi:10.1002/ajmg.c.31870.

    PMID: 33277783
  17. 17

    Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.

    Bonesteele G, Gargus JJ, Curtin E, et al.

    Molecular genetics and metabolism reports 2020; (25()):100663 doi:10.1016/j.ymgmr.2020.100663.

    PMID: 33101982
  18. 18

    Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1.

    Dardis A, Michelakakis H, Rozenfeld P, et al.

    Orphanet journal of rare diseases 2022; (17(1)):442 doi:10.1186/s13023-022-02573-6.

    PMID: 36544230

This page provides information on long-term monitoring and secondary health risks for GD1. It is for educational purposes only and does not replace personalized medical advice or scheduled monitoring from your healthcare team.

Get notified when new evidence is published on Gaucher disease type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.